StockNews.com began coverage on shares of iBio (NYSEAMERICAN:IBIO – Free Report) in a research note issued to investors on Wednesday morning. The firm issued a sell rating on the stock.
iBio Trading Up 20.8 %
Shares of NYSEAMERICAN:IBIO opened at $4.06 on Wednesday. iBio has a 1 year low of $1.02 and a 1 year high of $49.00. The company has a current ratio of 0.91, a quick ratio of 0.91 and a debt-to-equity ratio of 0.04.
iBio (NYSEAMERICAN:IBIO – Get Free Report) last announced its quarterly earnings results on Friday, February 9th. The company reported ($2.42) earnings per share (EPS) for the quarter.
About iBio
iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.
Read More
- Five stocks we like better than iBio
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- 3 Value Stocks Too Small For Buffett’s Portfolio
- How to Buy Cheap Stocks Step by Step
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- 3 Warren Buffett Stocks to Buy Now
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
